EMA Authorised: Spinraza (nusinersen sodium) — Biogen Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Spinraza (nusinersen) by Biogen Netherlands B.V. for spinal muscular atrophy, with orphan medicine designation and acce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Spinraza (nusinersen)

Snippet

Status: Authorised. Therapeutic area: Muscular Atrophy, Spinal. MAH: Biogen Netherlands B.V.. Decision date: 09/01/2026. Orphan medicine. Accelerated assessment